Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments
In recent years, the issue of accepting a higher cost per health improvement for orphan drugs has been the subject of discussion in health care policy agencies and the academic literature. This article aims to provide an analysis of broadly egalitarian arguments for and against accepting higher cost...
| Authors: | ; ; ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley-Blackwell
[2021]
|
| In: |
Bioethics
Year: 2021, Volume: 35, Issue: 4, Pages: 307-314 |
| IxTheo Classification: | NCC Social ethics NCH Medical ethics |
| Further subjects: | B
Opportunity Cost
B cost-effectiveness B Health economics B orphan drugs B Equality B drug prices B priority setting |
| Online Access: |
Presumably Free Access Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1756658544 | ||
| 003 | DE-627 | ||
| 005 | 20230426092551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210430s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bioe.12786 |2 doi | |
| 035 | |a (DE-627)1756658544 | ||
| 035 | |a (DE-599)KXP1756658544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |e VerfasserIn |0 (DE-588)173674844 |0 (DE-627)674763769 |0 (DE-576)356396029 |4 aut |a Juth, Niklas |d 1973- | |
| 109 | |a Juth, Niklas 1973- | ||
| 245 | 1 | 0 | |a Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments |
| 264 | 1 | |c [2021] | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In recent years, the issue of accepting a higher cost per health improvement for orphan drugs has been the subject of discussion in health care policy agencies and the academic literature. This article aims to provide an analysis of broadly egalitarian arguments for and against accepting higher costs per health improvement. More specifically, we aim to investigate which arguments one should agree upon putting aside and where further explorations are needed. We identify three kinds of arguments in the literature: considerations of substantial equality, formal equality, and opportunity cost. We argue that considerations of substantial equality do not support higher costs per health improvement orphan drugs, even if such considerations are considered valid. On the contrary, arguments of formal equality may support accepting a higher cost per health improvement for orphan drugs. However, in order to do so, a number of both normative and empirical issues must be resolved; these issues are identified in the article. For instance, it must be settled to what extent the opportunity cost in terms of foregone health for other patients is acceptable in order to uphold formal equality. We conclude that certain arguments can be set aside, and future focus should be put on the unresolved normative and empirical issues related to formal equality and opportunity cost. | ||
| 601 | |a Argumentation | ||
| 650 | 4 | |a cost-effectiveness | |
| 650 | 4 | |a drug prices | |
| 650 | 4 | |a Equality | |
| 650 | 4 | |a Health economics | |
| 650 | 4 | |a Opportunity Cost | |
| 650 | 4 | |a orphan drugs | |
| 650 | 4 | |a priority setting | |
| 652 | |a NCC:NCH | ||
| 700 | 1 | |a Gustavsson, Erik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Henriksson, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sandman, Lars |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioethics |d Oxford [u.a.] : Wiley-Blackwell, 1987 |g 35(2021), 4, Seite 307-314 |h Online-Ressource |w (DE-627)271596708 |w (DE-600)1480658-7 |w (DE-576)078707986 |x 1467-8519 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:4 |g pages:307-314 |
| 856 | |u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bioe.12786 |x unpaywall |z Vermutlich kostenfreier Zugang |h publisher [open (via crossref license)] | ||
| 856 | 4 | 0 | |u https://doi.org/10.1111/bioe.12786 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.12786 |x Verlag |z lizenzpflichtig |3 Volltext |
| 936 | u | w | |d 35 |j 2021 |e 4 |h 307-314 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 3920247086 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1756658544 | ||
| LOK | |0 005 20220127113356 | ||
| LOK | |0 008 210430||||||||||||||||ger||||||| | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixzo | ||
| LOK | |0 936ln |0 1550736558 |a NCH | ||
| LOK | |0 936ln |0 144205283X |a NCC | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||